๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma

โœ Scribed by Frederick B. Stehman; John A. Blessing; Howard D. Homesley; John L. Currie; Edgardo L. Yordan

Publisher
Springer US
Year
1984
Tongue
English
Weight
139 KB
Volume
2
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m 2/wk with escalation to 75 mg/m z/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

๐Ÿ“œ SIMILAR VOLUMES

Phase II evaluation of menogaril in pati
Phase II evaluation of menogaril in patients with advanced cervical carcinoma
โœ Harry J. Long; Harry S. Wieand; John F. Foley; Robert D. Niedringhaus; John A. L ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer US ๐ŸŒ English โš– 170 KB

Fourteen patients with advanced/recurrent squamous cell carcinoma of the uterine cervix received menogaril, 200 mg/m 2 by one hour intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was less than two months and median survival was seven mo

Mitoxantrone in the treatment of advance
Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (A phase II trial of the gynecologic oncology group)
โœ Hyman B. Muss; Brian N. Bundy; Howard D. Homesley; George Wilbanks ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer US ๐ŸŒ English โš– 247 KB

Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m 2 every three weeks. All patients had good performance status and measurable disease and'only 11 had received prior chemotherapy. One complete and one partial response wer

Phase II study of mitoxantrone in advanc
Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck
โœ Stephen D. Williams; Robert Birch; Enrique Velez-Garcia; Richard Gams ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 170 KB

A phase II study of mitoxantrone in squamous cell carcinoma of head and neck origin was conducted. Fiftythree evaluable patients were treated with this agent at a dosage of 5 mg/M2/week. The majority of patients were of high performance status. Twenty-seven patients had received previous chemotherap